Talphera, Inc. (TLPH)
For informational purposes only. Not financial advice.
Talphera, Inc. (TLPH) is a publicly traded company trading at $1.23 with a market cap of 25235438. It holds a moderate AI score of 52/100 based on fundamental, technical, and sentiment analysis.
Talphera, Inc. is a specialty pharmaceutical company focused on developing therapies for medically supervised settings. Their lead product, Niyad, is under investigation as an anticoagulant.
Company Overview
Talphera, Inc. (TLPH) pioneers therapies for medically supervised settings, with Niyad as a lead anticoagulant candidate, offering a compelling investment in specialized pharmaceutical solutions and innovative treatments targeting critical medical needs and improved patient outcomes. The company's pipeline offers additional upside.
Investment Thesis
Talphera, Inc. presents a compelling investment opportunity within the specialty pharmaceutical sector. The company's focus on therapies for medically supervised settings, particularly its lead product candidate Niyad, addresses a critical need for improved anticoagulation solutions. Successful development and commercialization of Niyad could drive significant revenue growth. Furthermore, the potential of LTX-608 as an anti-inflammatory and antiviral treatment offers substantial upside, especially given the ongoing need for effective therapies against COVID-19 and other respiratory illnesses. While the company's current financials reflect negative profitability, the successful advancement of its pipeline could transform its financial performance. Investors should consider the inherent risks associated with pharmaceutical development, but the potential rewards of Talphera's innovative therapies make it an attractive investment.
Key Highlights
- Market capitalization of $0.02 billion reflects its current valuation and potential for growth.
- Negative P/E ratio of -2.64 indicates the company's current lack of profitability, but also its potential for future earnings growth.
- Profit margin of -44242.9% highlights the significant expenses associated with pharmaceutical development and commercialization.
- Gross margin of -8803.6% reflects the cost of goods sold exceeding revenue, indicating a need for improved operational efficiency.
- Beta of 0.47 suggests lower volatility compared to the overall market, potentially appealing to risk-averse investors.
Competitors
Strengths
- Specialized product pipeline.
- Focus on medically supervised settings.
- Innovative drug delivery systems.
Weaknesses
- Negative profitability.
- Limited financial resources.
- Reliance on successful clinical trials.
Catalysts
- Upcoming: Completion of Niyad's investigational device exemption process.
- Upcoming: Clinical trial results for LTX-608.
- Ongoing: Potential strategic partnerships.
- Ongoing: Regulatory approvals for Fedsyra and PFS-02.
Risks
- Potential: Clinical trial failures.
- Potential: Regulatory delays.
- Ongoing: Competition from established pharmaceutical companies.
- Ongoing: Dependence on key personnel.
Growth Opportunities
- Niyad Commercialization: Successful completion of the investigational device exemption process and subsequent commercialization of Niyad as an anticoagulant for extracorporeal circuits represents a significant growth opportunity. The market for anticoagulants is substantial, and Niyad's unique lyophilized formulation could offer advantages over existing therapies. Timeline: 2027-2028.
- LTX-608 Development: Advancing the development of LTX-608 as an anti-inflammatory and antiviral treatment for conditions such as COVID-19, DIC, ARDS, and acute pancreatitis offers a broad range of potential applications. The market for these indications is significant, and successful clinical trials could lead to substantial revenue generation. Timeline: 2028-2030.
- Fedsyra and PFS-02 Commercialization: The commercialization of Fedsyra, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe, can streamline medication administration in emergency situations. These products address the need for rapid and accurate dosing of critical medications, potentially capturing a niche market within the emergency medicine sector. Timeline: 2026-2027.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies or healthcare providers could provide Talphera with access to additional resources, expertise, and distribution channels. These partnerships could accelerate the development and commercialization of its pipeline products. Timeline: Ongoing.
- Geographic Expansion: Expanding into new geographic markets, particularly in Europe and Asia, could significantly increase Talphera's revenue potential. These markets offer substantial opportunities for its therapies, particularly if they address unmet medical needs in those regions. Timeline: 2029-2031.
Opportunities
- Commercialization of Niyad.
- Development of LTX-608.
- Strategic partnerships.
Threats
- Regulatory hurdles.
- Competition from larger pharmaceutical companies.
- Clinical trial failures.
Competitive Advantages
- Specialized product pipeline focused on niche medical needs.
- Proprietary formulations and drug delivery systems.
- Intellectual property protection through patents and exclusivity.
About
Talphera, Inc., formerly known as AcelRx Pharmaceuticals, Inc., is a specialty pharmaceutical company dedicated to the development and commercialization of innovative therapies for use in medically supervised settings. Founded in 2005 and headquartered in San Mateo, California, Talphera focuses on addressing unmet needs in acute care environments. The company's lead product candidate, Niyad, a lyophilized formulation of nafamostat, is currently under an investigational device exemption as an anticoagulant for the extracorporeal circuit. This positions Talphera at the forefront of providing solutions for critical care procedures. Beyond Niyad, Talphera is also developing LTX-608, an anti-inflammatory and antiviral treatment with potential applications for COVID-19, disseminated intravascular coagulation (DIC), acute respiratory distress syndrome (ARDS), and acute pancreatitis. Furthermore, the pipeline includes Fedsyra, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe, both designed to improve the ease of use and safety of critical medications. Talphera's strategic focus on medically supervised settings and its pipeline of innovative therapies positions it as a key player in the specialty pharmaceutical market, aiming to improve patient outcomes and streamline medical procedures.
What They Do
- Develop therapies for medically supervised settings.
- Focus on acute care environments.
- Develop Niyad, an anticoagulant for extracorporeal circuits.
- Develop LTX-608, an anti-inflammatory and antiviral treatment.
- Develop Fedsyra, a pre-filled ephedrine syringe.
- Develop PFS-02, a pre-filled phenylephrine syringe.
Business Model
- Develop and commercialize specialty pharmaceutical products.
- Generate revenue through product sales.
- Focus on therapies for medically supervised settings.
Industry Context
Talphera operates in the specialty pharmaceutical industry, a segment characterized by high research and development costs, stringent regulatory requirements, and significant market competition. The industry is driven by the need for innovative therapies that address unmet medical needs. Talphera's focus on medically supervised settings aligns with the growing demand for specialized treatments in acute care environments. Competitors like Apellis Pharmaceuticals (APUS), Cosmos Health (COSM), iBio (IBIO), INTS and ITRM are also vying for market share. The global pharmaceuticals market is projected to reach trillions of dollars by 2026, presenting substantial opportunities for companies with innovative and effective therapies.
Key Customers
- Hospitals
- Clinics
- Medical Professionals
Financials
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $1,000 | -$4M | $-0.11 |
| Q1 2025 | $27,000 | -$3M | $-0.10 |
Source: Company filings
Chart & Info
Price Chart
Talphera, Inc. (TLPH) stock price: $1.23 (+0.07, +6.03%)
Why Bull
- •Recent insider buying activity indicates confidence from leadership in Talphera's future prospects.
- •Community sentiment has shifted positively, with discussions highlighting the company's innovative approaches in its sector.
- •Analysts have noted increasing interest in Talphera's product pipeline, suggesting potential for significant market impact.
- •Positive news coverage has emerged regarding Talphera's recent partnerships, enhancing its reputation and visibility in the industry.
Why Bear
- •Some investors express concerns about the company's cash flow stability, which could hinder growth initiatives.
- •There are lingering doubts about the scalability of Talphera's technologies, as market competition intensifies.
- •Social sentiment reflects apprehension regarding regulatory hurdles that could delay product launches.
- •Recent bearish commentary in trading forums emphasizes skepticism about the company's long-term strategic direction.
Latest News
-
12 Health Care Stocks Moving In Monday's Pre-Market Session
benzinga · Feb 23, 2026
-
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga · Feb 11, 2026
Technical Analysis
Rationale
AI-generated technical analysis for TLPH including trend direction, momentum, and pattern recognition.
What to Watch
Key support and resistance levels, volume signals, and upcoming events.
Risk Management
Position sizing, stop-loss levels, and risk-reward assessment.
Community
Discussion
Share your analysis and discuss Talphera, Inc. (TLPH) with other investors. Log in to post.
Sentiment
Community sentiment and discussion activity for TLPH.
Make a Prediction
Set your price target for Talphera, Inc. (TLPH), choose a timeframe, and track your prediction accuracy.
Current price: $1.23 · Analyst target: $3.25
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for TLPH.
Price Targets
Consensus target: $3.25
Insider Flow (30d)
MoonshotScore
Score Factors
-
Revenue Growth 5/100
Revenue growth data is currently unavailable for this company.
-
Gross Margin 3/100
Gross margin of -8800.0% is below average, suggesting thin margins and potential pricing pressure.
-
Operating Leverage 4/100
Limited operating leverage due to slower revenue growth, keeping profit scaling constrained.
-
Cash Runway 5/100
Limited cash of $9M could constrain flexibility; watch for dilution risk or debt issuance.
-
R&D Intensity 5/100
R&D spending data is currently unavailable for this company.
-
Insider Activity 8/100
Moderate net insider buying of +$0.18M suggests management sees value at current price levels.
-
Short Interest 10/100
Daily turnover of 1.91% indicates healthy liquidity with smooth entry/exit for investors.
-
Price Momentum 3/100
Weak momentum with few bullish signals. The stock may be in a downtrend or consolidation phase.
-
News Sentiment 5/100
No sentiment data available
What does this score mean?
The MoonshotScore rates TLPH's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Competitors & Peers
Frequently Asked Questions
What does Talphera, Inc. do?
Talphera, Inc. is a specialty pharmaceutical company that focuses on developing and commercializing therapies for use in medically supervised settings. Their lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit. Additionally, they are developing LTX-608, an anti-inflammatory and antiviral treatment, as well as pre-filled syringes like Fedsyra and PFS-02. The company aims to address unmet medical needs in acute care environments through innovative therapies and improved drug delivery systems.
Is TLPH stock a good buy?
TLPH stock represents a high-risk, high-reward investment opportunity. The company's negative profitability and reliance on successful clinical trials present significant risks. However, the potential commercialization of Niyad and the development of LTX-608 offer substantial upside. Investors should carefully consider their risk tolerance and conduct thorough due diligence before investing. A positive outcome in clinical trials and subsequent regulatory approvals could significantly increase the stock's value. The current market cap of $0.02 billion suggests considerable growth potential if the company's pipeline progresses successfully.
What are the main risks for TLPH?
The main risks for TLPH include the potential for clinical trial failures, regulatory delays, and competition from established pharmaceutical companies. The company's financial position is also a concern, as it currently operates with negative profitability and limited resources. Dependence on key personnel and the ability to secure additional funding are also significant risks. Investors should be aware of these challenges and carefully assess their potential impact on the company's future performance. Unfavorable outcomes in any of these areas could negatively affect the stock price.
Is TLPH a good stock to buy?
Whether TLPH is a suitable investment depends on your goals, risk tolerance, and time horizon. Evaluate Talphera, Inc.'s revenue growth, profit margins, debt levels, and valuation relative to peers. This is not financial advice.
What is the TLPH MoonshotScore?
The MoonshotScore rates TLPH from 0 to 100 across growth potential, financial health, market momentum, and risk factors. Scores above 70 suggest strong potential, 50-70 moderate, and below 50 warrants caution. It is recalculated daily using the latest market data. This score is informational only.
How often is TLPH data updated?
TLPH prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What do analysts say about TLPH?
Analyst coverage for TLPH includes consensus ratings (buy, hold, sell), 12-month price targets, and earnings estimates from major research firms. Key data points: consensus target price, number of covering analysts, recent upgrades or downgrades, and earnings beat/miss history. See the Analyst Consensus section on this page.
What are the risks of investing in TLPH?
Risk categories for TLPH include market risk, company-specific risk (management, competition), financial risk (debt, cash burn), and macroeconomic risk (rates, inflation). Beta above 1.0 indicates higher volatility than the S&P 500. Review the Risk Factors section on this page for details. All investments carry risk of loss.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Data provided for informational purposes only.
- Information is based on available sources and may be subject to change.
- Investment decisions should be based on individual risk tolerance and due diligence.